NDAINJECTIONINJECTABLE
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
3
Data completeness
4/8 — Partial
ANTIZOL (fomepizole) by R-Pharm US is clinical pharmacology mechanism of action: antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase. First approved in 1997.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Antizol (fomepizole) is a competitive alcohol dehydrogenase inhibitor administered intravenously for acute poisoning with ethylene glycol or methanol. It works by blocking the enzyme that converts these toxic compounds into their lethal metabolites, preventing metabolic acidosis and organ damage. The drug is a critical intervention in emergency toxicology with narrow therapeutic windows and life-or-death clinical significance.
LOE Approaching1.0 years to LOE
Product is approaching loss of exclusivity in 2027 with minimal linked job openings, indicating a specialized, lean commercial footprint typical of niche emergency-use therapeutics.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action: Antizol (fomepizole) is a competitive inhibitor of alcohol dehydrogenase. Alcohol dehydrogenase catalyzes the oxidation of ethanol to acetaldehyde. Alcohol dehydrogenase also catalyzes the initial steps in the metabolism of ethylene glycol and methanol to…
Worked on ANTIZOL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.